All News
Filter News
Found 83 articles
-
Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor
1/7/2022
Nuvalent, Inc. today announced that the first patient has been dosed in ARROS-1, its Phase 1/2 clinical trial evaluating NVL-520
-
Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Nuvalent, Inc. today announced that James Porter , Ph.D., Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 , at 11:15 a.m. ET.
-
Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results
11/10/2021
Nuvalent, Inc. today reported recent pipeline progress and third quarter 2021 financial results.
-
New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC
10/7/2021
Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, provided new preclinical data on Thursday supporting advancement of its parallel lead programs in non-small cell lung cancer (NSCLC).
-
During the past two years, fundraising and investment in biotechnology have reached record levels.
-
Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
9/8/2021
Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, reported recent pipeline and business highlights and second quarter 2021 financial results.
-
Show me the money! This week's who's who of IPOs and financing rounds in the biopharma world.
-
Nuvalent Announces Closing of Upsized Initial Public Offering
8/2/2021
Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its upsized initial public offering of 11,212,500 shares of common stock,
-
Nuvalent, Rallybio and Icosavax all began selling on the Nasdaq Exchange today.
-
Nuvalent Announces Pricing of Initial Public Offering
7/29/2021
Nuvalent, Inc. announced the pricing of its initial public offering of 9,750,000 shares of common stock, consisting of 9,150,000 shares of Class A common stock and 600,000 shares of Class B common stock, each at a price to the public of $17.00 per share.
-
The research collaboration will see the development of bispecific antibodies and CAR-T cell products.
-
Money on the Move: May 5 - 11
5/12/2021
Catch up on the investment news quickly with BioSpace's brief overview of the biotech companies hitting the Nasdaq and raking in fresh cash the past week. -
2021 is shaping up to be another banner year for biotech companies as they advance the next gen technologies and therapeutics for the health of all. Here’s a few raking in cash for their programs today.
-
Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
5/11/2021
Funding to Advance Parallel Lead Programs in ROS1-positive and ALK-positive NSCLC to Phase 1/2 Clinical Trials and Expand Discovery Research Pipeline
-
Nuvalent Presents Preclinical Data Demonstrating That ROS1 Inhibitor NUV-520 and ALK Inhibitor NUV-655 are Selective, Brain-Penetrant, and Active Against Drug-Resistance Mutations
4/10/2021
Preclinical data presented at the 2021 AACR Annual Virtual Meeting supports advancement of parallel lead programs in ROS1-positive and ALK-positive NSCLC
-
ixlayer Expands Partnership with On-Demand Logistics Service Senpex to Provide Same-Day Delivery of Lab Tests to Patients, Hospitals and Clinical Labs
4/6/2021
ixlayer, a leader in technology-based solutions for diagnostic testing, today announced its expanded relationship with Senpex, an on-demand last mile logistics service powered by artificial intelligence, to make COVID-19 tests more accessible to patients by providing same-day delivery options to health systems and clinical labs.
-
BioSpace Movers & Shakers, March 26
3/26/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer
3/23/2021
Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, announced the appointment of Christopher Turner, M.D., as Chief Medical Officer.
-
The duo launch Riverway Discoveries to drive the development and commercialization of new cancer therapeutics faster into patient's hands.
-
A recap of where life sciences cash has been flowing the past week.